AI-extracted from the 10-Q filed 2026-08-05 — Q2 FY2026 (quarter ended July 3, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.
Q2 revenue grew 10.3% YoY to $265.8M, with operating income up 21.1%, but SG&A expenses surged 27.4% driven by acquisition planning and system implementation costs.
Biggest Revenue Drivers
Automation Enabling Technologies$136.2M+12.0% YoY
Increase in sales of robotics and automation and precision manufacturing products.
Medical Solutions$129.6M+8.6% YoY
Increase in sales of advanced surgery and precision medicine products.
Biggest Revenue Drivers
Total revenue: $265.8M+10.3% YoY
Automation Enabling Technologies$136.2M+12.0% YoY
Increase in sales of robotics and automation and precision manufacturing products.
Medical Solutions$129.6M+8.6% YoY
Increase in sales of advanced surgery and precision medicine products.
Largest Expense Items
Cost of revenue$144.9M+7.8% YoY
Increased material inflationary costs and tariffs, partially offset by higher volumes and pricing.
Selling, general and administrative$60.0M+27.4% YoY
Higher variable employee compensation and costs for financial and operations system implementation planning and design.
Research and development and engineering$24.0M-5.2% YoY
Lower spending on R&D projects.
Restructuring, acquisition, and related costs$12.5M-0.6% YoY
Decrease in restructuring charges offset by increase in acquisition-related costs.
Watch Items from the Filing
Riverpoint Medical acquisition closed July 23, 2026 for $1.2B upfront plus $250M milestone payment due January 8, 2027, funded with $616M revolving/delayed draw borrowings, increasing total debt to $854.8M and reducing leverage headroom materially.
Foreign currency exchange favorably impacted Q2 revenue by $2.4M (1.0%); unfavorable FX swings could reverse, creating revenue headwind if dollar strengthens.
Company facing supply chain constraints on rare-earth materials sourced from China requiring export licenses; unable to obtain necessary licenses for several months, causing order fulfillment delays and manufacturing cost increases.
Contract liabilities surged from $11.1M to $48.0M, primarily from advance customer payment on supply agreement; unwind of this liability will reduce future revenue recognition timing.
AI-extracted and verified against SEC EDGAR filing text. Not investment advice.
6 transactions in NOVT reported by 3 members of Congress under the STOCK Act, most recent trade May 18, 2026. Reported transactions, not recommendations.
About NOVANTA INC (NOVT): stock profile, AI score and financials
NOVANTA INC (NOVT) stock profile, AI quality score, and SEC EDGAR financial data, a Technology sector company. 13F Pro's AI-powered ranking engine scores NOVT at 52.6/100 on a composite quality score built from its SEC filings, placing it at rank #1,461 of 2,925 stocks — the top half of the AI-ranked universe. Areas of concern include institutional flow (32.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 31.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), NOVANTA INC reports quarterly revenue of $265.8M, net income of $12.5M, an operating margin of 6.8%. Top institutional holders of NOVT by reported 13-F value include BlackRock, VANGUARD PORTFOLIO MANAGEMENT, PRICE T ROWE ASSOCIATES, based on the most recent SEC filings. NOVT trades on the Nasdaq exchange and files with the SEC under CIK 1076930. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate NOVT daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for NOVANTA INC directly from SEC EDGAR.